Company intelligence / Profile preview
Bio 54
Raleigh, North Carolina, United Statesbio54.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Bio 54 has advanced its lead candidate BXP-154, a small molecule drug for the treatment of hemorrhage, into Phase 2 clinical trials. One completed randomized, double-blind, placebo-controlled study evaluated the efficacy and safety of BXP154B (Tranexamic Acid Sterile Topical Solution) for external bleeding from minor wounds in subjects on apixaban. No detailed results are publicly available.
- Therapeutic areas
- Hematology
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Bio 54.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bio 54.